Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Account Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Change in Account Payables for 4 consecutive years, with -$229076.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 251.53% to -$229076.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $157823.0, a 164.9% increase, with the full-year FY2024 number at $382521.0, up 2737.89% from a year prior.
  • Change in Account Payables was -$229076.0 for Q3 2025 at bioAffinity Technologies, down from -$211741.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $577474.0 in Q3 2023 to a low of -$435285.0 in Q3 2022.
  • A 4-year average of $29073.7 and a median of $17284.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 1248.49% in 2023, then surged 1565.44% in 2024.
  • bioAffinity Technologies' Change in Account Payables stood at $195360.0 in 2022, then tumbled by 315.67% to -$421337.0 in 2023, then surged by 148.51% to $204373.0 in 2024, then plummeted by 212.09% to -$229076.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Change in Account Payables are -$229076.0 (Q3 2025), -$211741.0 (Q2 2025), and $394267.0 (Q1 2025).